Artemis Medicare Services Ltd is Rated Buy

29 minutes ago
share
Share Via
Artemis Medicare Services Ltd is rated Buy by MarketsMojo, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 September 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.
Artemis Medicare Services Ltd is Rated Buy

Current Rating and Its Significance

MarketsMOJO’s Buy rating for Artemis Medicare Services Ltd indicates a positive outlook on the stock’s potential for growth and value creation. This rating reflects a comprehensive assessment of the company’s quality, valuation, financial trend, and technical indicators. Investors should understand that a Buy rating suggests the stock is expected to outperform the broader market or its sector peers over the medium to long term, making it a favourable addition to a diversified portfolio.

Quality Assessment

As of 30 September 2026, Artemis Medicare Services Ltd demonstrates strong operational quality. The company holds a good quality grade, supported by its consistent ability to generate profits and maintain financial discipline. Notably, the company has declared positive results for ten consecutive quarters, underscoring its stable earnings trajectory. The return on capital employed (ROCE) for the half-year period stands at a healthy 14.21%, indicating efficient utilisation of capital to generate profits.

Additionally, Artemis maintains a low debt-equity ratio of 0.28 times, reflecting prudent leverage management. Its operating profit to interest coverage ratio is robust at 8.74 times, signalling strong capacity to service debt obligations without strain. These factors collectively contribute to the company’s solid quality profile, reassuring investors of its operational resilience.

Valuation Perspective

The valuation grade for Artemis Medicare Services Ltd is currently assessed as fair. The stock trades at a price-to-book value of 6.2, which, while elevated, is justified by the company’s growth prospects and profitability metrics. Compared to its peers, Artemis is trading at a discount relative to historical valuations, offering a reasonable entry point for investors seeking exposure to the hospital sector.

The company’s return on equity (ROE) is 11.3%, which aligns with its valuation, suggesting that investors are paying a fair price for the earnings generated. The price/earnings to growth (PEG) ratio stands at 3, indicating that while growth expectations are priced in, the stock still offers potential upside given its earnings momentum.

Financial Trend Analysis

Financially, Artemis Medicare Services Ltd is on a positive trajectory. The company’s operating profit has grown at an annualised rate of 33.45%, reflecting strong underlying business expansion. Over the past year, profits have increased by 32.9%, demonstrating sustained earnings growth that supports the Buy rating.

Stock returns further reinforce this trend. As of 30 September 2026, the stock has delivered a remarkable 51.28% return over the past year and an impressive 72.25% gain over six months. Year-to-date returns stand at 30.46%, with a three-month return of 33.44%, all of which significantly outperform the broader BSE500 index. This market-beating performance highlights the company’s ability to generate shareholder value consistently.

Technical Outlook

The technical grade for Artemis Medicare Services Ltd is bullish, reflecting positive momentum in the stock price and favourable market sentiment. Despite a minor one-day decline of 3.49%, the stock’s medium and long-term trends remain strong, supported by steady volume and price appreciation. This technical strength complements the fundamental positives, providing an additional layer of confidence for investors considering the stock.

Summary of Current Position

In summary, Artemis Medicare Services Ltd’s Buy rating is underpinned by a combination of solid quality metrics, fair valuation, positive financial trends, and bullish technical indicators. The company’s ability to maintain low leverage, deliver consistent profit growth, and outperform market benchmarks makes it an attractive proposition for investors seeking exposure to the hospital sector’s growth potential.

Investors should note that while the rating was updated on 08 June 2026, all financial data and returns discussed here are current as of 30 September 2026, ensuring a timely and relevant perspective on the stock’s investment merits.

Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.

  • - Market-beating performance
  • - Committee-backed winner
  • - Aluminium & Aluminium Products standout

Read the Winning Analysis →

Investor Considerations

For investors evaluating Artemis Medicare Services Ltd, the Buy rating signals a favourable risk-reward profile. The company’s strong fundamentals and growth prospects suggest it is well-positioned to capitalise on expanding healthcare demand. However, the fair valuation and PEG ratio indicate that investors should monitor earnings growth closely to ensure it continues to justify the current price levels.

Moreover, the company’s low leverage and consistent profitability provide a cushion against market volatility, making it a relatively stable choice within the smallcap hospital sector. The bullish technical outlook further supports the case for accumulation, particularly for investors with a medium to long-term horizon.

Sector and Market Context

Within the hospital sector, Artemis Medicare Services Ltd stands out for its operational efficiency and growth momentum. The sector itself is benefiting from increasing healthcare expenditure and rising demand for quality medical services, which bodes well for companies with strong fundamentals like Artemis.

Compared to the broader market, Artemis has outperformed key indices such as the BSE500 over multiple time frames, reinforcing its status as a market-beating stock. This relative strength is an important consideration for investors seeking to enhance portfolio returns through sector leaders.

Conclusion

Artemis Medicare Services Ltd’s Buy rating by MarketsMOJO reflects a comprehensive evaluation of its current strengths and market position as of 30 September 2026. The company’s good quality, fair valuation, positive financial trends, and bullish technical indicators combine to present a compelling investment case. While investors should remain vigilant to market dynamics and company performance, Artemis offers a promising opportunity for those looking to capitalise on growth in the hospital sector.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News